Harald Lahner

Essen, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Real-world data show limited efficacy of sequential cabozantinib treatment in RAIR-(P)DTC.

Real-world data show limited efficacy of sequential cabozantinib treatment in RAIR-(P)DTC.

Journal: Endocrine-related cancer

Published: November 07, 2025

Accuracy and reliability of a continuous glucose monitoring system with a focus on hypoglycaemia.

Accuracy and reliability of a continuous glucose monitoring system with a focus on hypoglycaemia.

Journal: Diabetes, obesity & metabolism

Published: October 31, 2025

Digital vs conventional glycemic monitoring in rare endocrine cancers: comparison of effectiveness during chemotherapy.

Digital vs conventional glycemic monitoring in rare endocrine cancers: comparison of effectiveness during chemotherapy.

Journal: Endocrine connections

Published: October 20, 2025

Secukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.

Secukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.

Journal: The Journal of clinical endocrinology and metabolism

Published: October 09, 2025

High incidence and poor prognosis of bone metastases in functioning small intestinal neuroendocrine tumors.

High incidence and poor prognosis of bone metastases in functioning small intestinal neuroendocrine tumors.

Journal: Frontiers in endocrinology

Published: August 05, 2025

Real-world efficacy and safety of selpercatinib in RET-mutant medullary thyroid cancer at a Tertiary Referral Center.

Real-world efficacy and safety of selpercatinib in RET-mutant medullary thyroid cancer at a Tertiary Referral Center.

Journal: European journal of endocrinology

Published: July 18, 2025

Lenvatinib as salvage therapy in advanced and progressive GI-NET.

Lenvatinib as salvage therapy in advanced and progressive GI-NET.

Journal: Endocrine-related cancer

Published: May 20, 2025

Importance of peptide receptor radionuclide therapy for the management of neuroendocrine tumours

Importance of peptide receptor radionuclide therapy for the management of neuroendocrine tumours

Journal: Radiologie (Heidelberg, Germany)

Published: April 14, 2025

Comprehensive Assessment of Multikinase Inhibitor Therapy Outcomes in RAIR-(P)DTC and MTC at a Tertiary Referral Center.

Comprehensive Assessment of Multikinase Inhibitor Therapy Outcomes in RAIR-(P)DTC and MTC at a Tertiary Referral Center.

Journal: The Journal of clinical endocrinology and metabolism

Published: February 06, 2025

PRRT plus holmium-166-SIRT (HEPAR PLuS) versus PRRT-only in patients with metastatic neuroendocrine tumors: A propensity-score matched analysis.

PRRT plus holmium-166-SIRT (HEPAR PLuS) versus PRRT-only in patients with metastatic neuroendocrine tumors: A propensity-score matched analysis.

Journal: Journal of neuroendocrinology

Published: January 21, 2025

Impact of functionality and grading on survival in pancreatic neuroendocrine tumor patients receiving peptide receptor radionuclide therapy.

Impact of functionality and grading on survival in pancreatic neuroendocrine tumor patients receiving peptide receptor radionuclide therapy.

Journal: Frontiers in endocrinology

Published: November 11, 2024

Somatostatin analogs in neuroendocrine tumors with Ki-67 index of ≥10.

Somatostatin analogs in neuroendocrine tumors with Ki-67 index of ≥10.

Journal: Journal of neuroendocrinology

Published: October 06, 2024

Showing 1-12 of 61

Last Updated: 09/26/2026